REASONS FOR PERFORMING STUDY: Three previously described NS1 mutant equine influenza viruses encoding carboxy-terminally truncated NS1 proteins are impaired in their ability to inhibit type I IFN production in vitro and are replication attenuated, and thus are candidates for use as a modified live influenza virus vaccine in the horse. HYPOTHESIS: One or more of these mutant viruses is safe when administered to horses, and recipient horses when challenged with wild-type influenza have reduced physiological and virological correlates of disease. METHODS: Vaccination and challenge studies were done in horses, with measurement of pyrexia, clinical signs, virus shedding and systemic proinflammatory cytokines. RESULTS: Aerosol or intranasal inoculation of horses with the viruses produced no adverse effects. Seronegative horses inoculated with the NS1-73 and NS1-126 viruses, but not the NS1-99 virus, shed detectable virus and generated significant levels of antibodies. Following challenge with wild-type influenza, horses vaccinated with NS1-126 virus did not develop fever (>38.5 degrees C), had significantly fewer clinical signs of illness and significantly reduced quantities of virus excreted for a shorter duration post challenge compared to unvaccinated controls. Mean levels of proinflammatory cytokines IL-1beta and IL-6 were significantly higher in control animals, and were positively correlated with peak viral shedding and pyrexia on Day +2 post challenge. CONCLUSION AND CLINICAL RELEVANCE: These data suggest that the recombinant NS1 viruses are safe and effective as modified live virus vaccines against equine influenza. This type of reverse genetics-based vaccine can be easily updated by exchanging viral surface antigens to combat the problem of antigenic drift in influenza viruses.
REASONS FOR PERFORMING STUDY: Three previously described NS1 mutant equine influenza viruses encoding carboxy-terminally truncated NS1 proteins are impaired in their ability to inhibit type I IFN production in vitro and are replication attenuated, and thus are candidates for use as a modified live influenza virus vaccine in the horse. HYPOTHESIS: One or more of these mutant viruses is safe when administered to horses, and recipient horses when challenged with wild-type influenza have reduced physiological and virological correlates of disease. METHODS: Vaccination and challenge studies were done in horses, with measurement of pyrexia, clinical signs, virus shedding and systemic proinflammatory cytokines. RESULTS: Aerosol or intranasal inoculation of horses with the viruses produced no adverse effects. Seronegative horses inoculated with the NS1-73 and NS1-126 viruses, but not the NS1-99 virus, shed detectable virus and generated significant levels of antibodies. Following challenge with wild-type influenza, horses vaccinated with NS1-126 virus did not develop fever (>38.5 degrees C), had significantly fewer clinical signs of illness and significantly reduced quantities of virus excreted for a shorter duration post challenge compared to unvaccinated controls. Mean levels of proinflammatory cytokines IL-1beta and IL-6 were significantly higher in control animals, and were positively correlated with peak viral shedding and pyrexia on Day +2 post challenge. CONCLUSION AND CLINICAL RELEVANCE: These data suggest that the recombinant NS1 viruses are safe and effective as modified live virus vaccines against equineinfluenza. This type of reverse genetics-based vaccine can be easily updated by exchanging viral surface antigens to combat the problem of antigenic drift in influenza viruses.
Authors: G Soboll; K M Nelson; E S Leuthner; R J Clark; R Drape; M D Macklin; W F Swain; C W Olsen; D P Lunn Journal: Vaccine Date: 2003-06-20 Impact factor: 3.641
Authors: H G Townsend; S J Penner; T C Watts; A Cook; J Bogdan; D M Haines; S Griffin; T Chambers; R E Holland; P Whitaker-Dowling; J S Youngner; R W Sebring Journal: Equine Vet J Date: 2001-11 Impact factor: 2.888
Authors: T M Chambers; R E Holland; L R Tudor; H G Townsend; A Cook; J Bogdan; D P Lunn; S Hussey; P Whitaker-Dowling; J S Youngner; R W Sebring; S J Penner; G L Stiegler Journal: Equine Vet J Date: 2001-11 Impact factor: 2.888
Authors: G Soboll; D W Horohov; B M Aldridge; C W Olsen; M W McGregor; R J Drape; M D Macklin; W F Swain; D P Lunn Journal: Vet Immunol Immunopathol Date: 2003-07-15 Impact factor: 2.046
Authors: Alida Ault; Alyse M Zajac; Wing-Pui Kong; J Patrick Gorres; Michael Royals; Chih-Jen Wei; Saran Bao; Zhi-yong Yang; Stephanie E Reedy; Tracy L Sturgill; Allen E Page; Jennifer Donofrio-Newman; Amanda A Adams; Udeni B R Balasuriya; David W Horohov; Thomas M Chambers; Gary J Nabel; Srinivas S Rao Journal: Vaccine Date: 2012-03-23 Impact factor: 3.641
Authors: Bin Zhou; Yan Li; Jessica A Belser; Melissa B Pearce; Mirco Schmolke; Anju X Subba; Zhengli Shi; Sherif R Zaki; Dianna M Blau; Adolfo García-Sastre; Terrence M Tumpey; David E Wentworth Journal: Vaccine Date: 2010-10-08 Impact factor: 3.641
Authors: Amir Ghorbani; Michael C Abundo; Hana Ji; Kara J M Taylor; John M Ngunjiri; Chang-Won Lee Journal: J Virol Date: 2020-12-22 Impact factor: 5.103
Authors: Thomas M Chambers; Udeni B R Balasuriya; Stephanie E Reedy; Ashish Tiwari Journal: Influenza Other Respir Viruses Date: 2013-12 Impact factor: 4.380
Authors: Marcin P Walkiewicz; Dipanwita Basu; Joseph J Jablonski; H Mario Geysen; Daniel A Engel Journal: J Gen Virol Date: 2010-09-29 Impact factor: 3.891
Authors: Christoph Jindra; Bettina Huber; Saeed Shafti-Keramat; Markus Wolschek; Boris Ferko; Thomas Muster; Sabine Brandt; Reinhard Kirnbauer Journal: PLoS One Date: 2015-09-18 Impact factor: 3.240